30 research outputs found
TABLE 3 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
AEs. Most common AEs are summarized by severity, severity based on NCI CTCAE criteria version 4.03</p
Supplementary Figure 1, Supplementary Table S1, and Supplementary Table S2. from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
Supplementary figure and tables</p
Representativeness of Study Participants from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
Representativeness of Study Participants</p
TABLE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
Tumor response according to RECIST v1.1 (investigator assessment) in response-evaluable patients</p
TABLE 1 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
Baseline patient demographics</p
FIGURE 2 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
A, Waterfall plot showing best overall response of evaluable patients on trial. Among 30 patients in the dataset, 24 patients were evaluated for best overall response and 6 patients were not evaluated. Among 24 with best overall response, 4 had PR, 15 had SD, and 5 had PD. For these 24 patients, 22 had percent change from baseline tumor size measured. Two patients who had progression due to unequivocal progression in non-target lesions did not have a tumor size measurement. B, Swimmers plot. All 30 patients treated on study are included. PR, SD, PD, death, and ongoing treatment are indicated.</p
FIGURE 3 from Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with <i>mTOR/AKT/PI3K</i> Pathway Alterations and Advanced Solid Malignancies
Oncoplot showing mutations and co-occurring alterations in the patients enrolled in this clinical trial.</p
Supplementary Table S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
Biochemical inhibition of FGFR by RLY-4008 and pan-FGFRi</p
Supplementary Figure S2 from RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across <i>FGFR2</i> Alterations and Resistance Mutations
Supplementary Figure 2. Treatment with RLY-4008 is well-tolerated and leads to dose-dependent inhibition of FGFR2 and tumor regression in multiple FGFR2-altered tumor models.</p